Portal de Periódicos da CAPES

Chemotherapy and lung cancer-present status

1966; Elsevier BV; Volume: 51; Issue: 3 Linguagem: Inglês

10.1016/s0022-5223(19)43347-3

1097-685X

George A. Higgins, Julius Wolf,

Lymphoma Diagnosis and Treatment

Summary Although surgical resection is the only curative therapeutic modality in bronchogenic carcinoma, improved methods of diagnosis and surgical therapy have offered little improvement in the salvage rate of patients suffering from this condition. Extensive efforts are in progress to find cancerocidal agents to be used either as definitive treatment or as an adjuvant to surgical resection. In addition, numerous technical methods to permit greater delivery of the cancerocidal drug into the tumor without severe toxicity to the patient have been developed. Although many of these agents do exert a temporary arresting effect on the growth of the primary tumor and to metastases, no “cure” or even significant prolongation of life has been reported. This paucity of positive results does not in any way justify the abandonment of searches for new chemotherapeutic agents or better methods of administering those now available. The nature of lung cancer makes it necessary that a systemic form of therapy be found to supplement local surgical removal before a better survival rate can be anticipated.